Rationale: YKL-40, was reported to positively correlate with the severity of the disease and inversely with the lung function. The purpose of the study is to investigate the hypothesis that Mepolizumab (MEP), a humanized anti IL-5 monoclonal antibody, could have a positive role in airway structural change. Methods: We analyzed 19 patients (age range 43-68, 10 females), with severe asthma and who had received MEP for at least 1 year. Clinical parameters (FEV1%, FVC%, FeNO levels, blood eosinophils, Asthma Control Test (ACT), Oral Corticosteroid (OCS) administration, Exhacerbations) and serum levels of YKL-40 were evaluated at baseline and after treatment. Results: After 12 months of MEP treatment, the blood eosinophil count decreased from 750 ± 470,2 eos/μL to 98,53 ± 53,21 eos/μL (p < 0.05). ACT score improved from 18,16±5,03 to 22,79±3,44 (p<0.05). Exacerbations decreased from 3.26± 2.51/year to 0.84± 1,92/year (p < 0.05). Steroid-dependent patients before MEP with a daily dose of 12.43 ± 7,77 mg prednisone decrease after TREATMENT with a mean of 2.10 ± 6.25 mg/day (p < 0.5). FeNO levels decreased from 75,32± 57,64 ppb at baseline to 53,67± 41,52 ppb after treatment. The FEV1% predicted increased significantly (73,11± 23,98 vs 81,26±18,16), whereas the FVC% predicted showed no significant change. Serum YKL-40 levels decreased significantly from 49,09± 20,39 ng/mL at baseline to 40,87± 17,31 ng/mL. (<0.05). Conclusions: The reported results show a significant association between FEV1% pre-treatment and serum YKL-40 change. Altogether, our findings support the hypothesis that MEP is able to reduce allergen-induced Th2 inflammation and tissue remodelling.